Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRATIO: reparixin add-on therapy for acute respiratory distress syndrome
2022-001612-25Phase 2Active
- Sponsor
- Dompé
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Reparixin + standard of care with Placebo + standard of care (2 arms). Started Jun 2022; status: active.
02
Drugs
reparixin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2022-001612-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001612-25.